Top

American Journal of Cardiovascular Drugs

Published in:

01-11-2002 | From The World Literature

Opinion and Evidence in Cardiovascular Therapeutics

Published in: American Journal of Cardiovascular Drugs | Issue 6/2002

Excerpt

1. Omapatrilat Enhances Neurohormone and Cytokine Levels in Chronic Heart Failure
2. Sirolimus-Eluting Stents Reduce Restenosis in Femoral Arteries
3. IV Magnesium Sulfate Lacks Efficacy in ST-Elevation Myocardial Infarction
4. Quality of Life Gains With Implantable Cardioverter Defibrillator vs Amiodarone in Ventricular Arrhythmias
5. Alteplase + Heparin Beneficial for Submassive Pulmonary Embolism
6. Amlodipine: Superior Ischemia Reduction?
7. Folic Acid + Cyanocobalamin Improves Coronary Endothelial Function
8. ACE Inhibitors Aspirin: Clinicall Important Benefits
9. Ramipril: Cardiovascular Benefits in High-Risk Women
10. Periprocedural β-Blockers Improve Survival After Percutaneous Coronary Intervention
11. Rofecoxib Increases Risk of Serious Coronary Heart Disease
12. Losartan vs Atenolol in Isolated Systolic Hypertension
13. Lercanidipine, Losartan, Comparable in Hypertension
14. Sildenafil Well-Tolerated in Congestive Heart Failure
15. Coumarin + Aspirin Cost Saving for Coronary Angioplasty in The Netherlands
16. Valsartan: BP-Independent Antiproteinuric Effects
17. Torasemide for Chronic Heart Failure: TORIC Study Findings
18. Aspirin: First Choice For Preventing Recurrent Stroke?
19. Valsartan + Fluvastatin: Additive Anti-Oxidative Effect
20. Aspirin + β-Blocker Therapy Underused Following Myocardial Infarction
21. Losartan vs Captopril After Acute Myocardial Infarction
22. Desirudin vs Heparin: Effects on Thrombin
23. Gender Influences Blood Pressure Response to Perindopril/Indapamide
24. IV/IA vs IA Thrombolytics for Acute Stroke
25. Homocysteine-Lowering Therapy After Coronary Angioplasty

…

Inpharma Weekly provides rapid alerts to news on drugs and drug therapy. Summarizing information selected from over 1 600 biomedical journals, this newsletter is produced by Adis International Limited and is available in a variety of formats. Please contact your nearest Adis office for subscription details.

95% of patients in the reperfusion therapy group received magnesium sulfate before or concurrently with the initiation of reperfusion.

Costs were those related to inpatient, outpatient and pharmacy services.

Alteplase was administered as a 10mg bolus followed by a 90mg continuous infusion over a period of 2 hours.

In both treatment groups, drug doses were titrated at 2 weeks to meet set targets. At study end, the mean doses for the study drugs were amlodipine 9.5mg, diltiazem 292.9mg, atenolol 89.8mg and isosorbide mononitrate 91.9mg.

The analysis included the Studies of Left Ventricular Dysfunction (SOLVD) Treatment and Prevention trials, the Acute Infarction Ramipril Efficacy (AIRE) trial, the Survival and Ventricular Enlargement (SAVE) trial, the Trandolapril in patients with reduced left ventricular function after acute myocardial infarction (TRACE) trial, and the Heart Outcomes Prevention and Evaluation (HOPE) trial.

Patients who began use of an individual NSAID during follow-up.

Treatment response was defined as a supine DBP of ≤90mm Hg and/or a decrease in supine DBP of ≥10mm Hg.

Costs (2000 values) were those associated with hospitalization, cardiac medications, drug monitoring and cardiac- and complication-related procedures.

The other diuretics group included 527 patients receiving furosemide 40 mg/day. Patients receiving torasemide or furosemide were permitted to take other additional diuretics.

The perindopril/indapamide dosages were 0/1.25, 2/0.625, 2/1.25, 4/0.625, 4/1.25, 4/2.5, 8/1.25, and 8/2.5mg per day.

Major adverse events consisted of death, nonfatal myocardial infarction, and repeat revascularization.

Sheth T, Parker T, Block A, et al. Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 2002; 90: 496–500PubMedCrossRef

Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting Stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002; 106: 1505–9.PubMedCrossRef

Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) trial: a randomizedd controlled trial. Lancet 2002; 360: 1189–96CrossRef

Hsu J, Uratsu C, Truman A, et al. Life after a ventricular arrhythmia. Am Heart J 2002; 44: 404–12CrossRef

Konstantinides S, Geibel A, Heusel G, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 2002; 347: 1143–50PubMedCrossRef

Deanfield JE, Detry J-M, Sellier P, et al. Medical treatment of myocardial ischemia in coronary artery disease: effect of drug regime and irregular dosing in the CAPE II trial. J Am Coll Cardiol 2002; 40: 917–25PubMedCrossRef

Willems FF, Aengevaeren WRM, Boers GHJ. Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 2002; 40: 766–72PubMedCrossRef

Teo KK, Yusuf S, Pfeffer M, et al. Effects of long-term treatment with angiotensinconverting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet 2002; 360: 1037–43PubMedCrossRef

Lonn E, Roccaforte R, Yi Q, et al. Effect of long-term therapy with ramipril in high-risk women. J Am Coll Cardiol 2002; 40: 693–702PubMedCrossRef

Chan AW, Quinn MJ, Bhatt DL, et al. Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. J Am Coll Cardiol 2002; 40: 669–75PubMedCrossRef

Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071–3PubMedCrossRef

Kjeldsen SE, Dahlf B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint reduction (LIFE) substudy. JAMA 2002; 288: 1491–8PubMedCrossRef

James IGV, Jones A, Davies P. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension. J Human Hyperten 2002; 16: 605–10CrossRef

Bocchi EA, Guimar G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction on congestive heart failure: a double-blind, placebocontrolled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002; 106: 1097–103PubMedCrossRef

Berg JM, Kelder JC, Plokker THW, et al. Costs and effectiveness of using coumarins before, during and after coronary angioplasty. Pharmacoeconomics 2002; 20: 847–53PubMedCrossRef

Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–8PubMedCrossRef

Opie LH, Parving H-H. Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection? Circulation 2002; 106: 643–5PubMedCrossRef

Cosn J, Dez J, TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Failure 2002; 4: 507–13CrossRef

Warlow C. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. Stroke 2002 Aug; 2137-8

Diener H-C. Aspirin therapy should be first-line treatment in secondary prevention of stroke - against. Stroke 2002; 33: 2138–9PubMedCrossRef

Donnan GA, Davis SM. Aspirin therapy should be first line: probably, but watch this space. Stroke 2002; 33: 2139–40PubMedCrossRef

Hussein O, Shneider J, Rosenblat M, et al. Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients. J Cardiovasc Pharmacol 2002; 40: 28–34PubMedCrossRef

McCullough PA, Sandberg KR, Borzak S, et al. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002; 144: 226–32PubMedCrossRef

Reddan DN. Therapy for cardiovascular disease in patients with chronic kidney disease: appropriate caution or the absence of data. Am Heart J 2002; 144: 206–7PubMedCrossRef

Dickstein K, Kjekshus J, OPTIMAAL Steering Committee, et al. Effects of losartan and Captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 2002; 360: 752–60PubMedCrossRef

Kottke-Marchant K, Bahit MC, Granger CB, et al. Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes: the GUSTO-IIb haemostasis substudy. Eur Heart J 2002; 23: 1202–12PubMedCrossRef

Vorchheimer DA, Fuster V. Thrombin inhibitors in acute coronary artery disease. Eur Heart J 2002; 23: 1142–4PubMedCrossRef

Safar ME, Myers MG, Leenen F, et al. Gender influence on the dose-ranging of a low-dose perindopril-indapamide combination in hypertension: effect on systolic and pulse pressure. J Hypertens 2002; 20: 1653–61PubMedCrossRef

Elliott HL. Gender differences with antihypertensive drug treatment. J Hypertens 2002; 20: 1491–2.PubMedCrossRef

Zaidat OO, Suarez JI, Santillan C, et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke 2002; 33: 1821–7PubMedCrossRef

Tong DD. Intra-arterial thrombolytic therapy for acute stroke: the debate continues. Stroke 2002; 33: 1827PubMed

Schnyder G, Roffi M, Flammer Y, et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA 2002; 288:973–9PubMedCrossRef

Title: Opinion and Evidence in Cardiovascular Therapeutics
Publication date: 01-11-2002
Publisher: Springer International Publishing
Published in: American Journal of Cardiovascular Drugs / Issue 6/2002
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI: https://doi.org/10.2165/00129784-200202060-00007

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Opinion and Evidence in Cardiovascular Therapeutics

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2002

Development of Radiocontrast Agents for Vascular Imaging

Racial Differences in Responses to Drug Treatment

Calcium Channel Antagonists in the Treatment of Hypertension

Turner Syndrome and the Heart

Strategies for Minimizing Hyperlipidemia After Cardiac Transplantation

Therapeutic Potential of Monoclonal Antibodies in Myocardial Reperfusion Injury